Monopar Therapeutics’ (MNPR) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $60.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. Raymond James Financial began coverage on Monopar Therapeutics in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $80.00 price target for the company. Oppenheimer began coverage on Monopar Therapeutics in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $77.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $74.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. HC Wainwright began coverage on shares of Monopar Therapeutics in a research report on Tuesday, August 26th. They set a “buy” rating and a $70.00 price objective for the company. Finally, Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $71.75.

Monopar Therapeutics Stock Up 4.6%

MNPR opened at $57.00 on Tuesday. Monopar Therapeutics has a 12 month low of $3.90 and a 12 month high of $58.94. The company has a fifty day simple moving average of $40.04 and a 200 day simple moving average of $37.25. The stock has a market cap of $351.69 million, a P/E ratio of -17.12 and a beta of 1.20.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. On average, equities research analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Chandler Robinson sold 16,800 shares of Monopar Therapeutics stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer owned 73,472 shares in the company, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kim R. Tsuchimoto sold 8,904 shares of Monopar Therapeutics stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director owned 11,486 shares of the company’s stock, valued at $459,440. The trade was a 43.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,504 shares of company stock valued at $1,700,160 in the last quarter. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of MNPR. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Monopar Therapeutics during the 2nd quarter worth approximately $34,000. AlphaQuest LLC bought a new position in Monopar Therapeutics during the first quarter worth $44,000. JPMorgan Chase & Co. boosted its position in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Monopar Therapeutics during the second quarter worth $80,000. Finally, New York State Common Retirement Fund bought a new position in Monopar Therapeutics during the second quarter worth $104,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.